Abstract Search

ea0029p803 | Endocrine tumours and neoplasia | ICEECE2012

Estradiol Potentiates the Inhibitory Effects of SOM230 on Prostate Cells in vitro Up-regulating Ligand Binding Domain Expression of SSTR2 and 5

Rossi V. , Visconti D. , Bellastella G. , Palumbo V. , Abbondanza C. , De Rosa C. , Bellastella A. , Sinisi A.

The effects in vitro and in vivo of somatostatin (SS) analogues are linked to the presence of specific binding sites on target cells. Estradiol (E2) may modulate the expression of SS receptors (SSTR) in some cell models, including breast cancer and pituitary cells. Aim of this study was to evaluate the effects of E2 on SSTR1-5 ligand binding domains (LBD) expression levels in prostate epithelial cells (PEC).Methods: We investigated the effe...

0 shares

ea0026p289 | Pituitary | ECE2011

ACTH-secreting pituitary adenomas express higher SSTR5 than SSTR2 protein levels by immunohistochenistry using new monoclonal antibodies against SST-binding domains

Rossi V , Bellastella G , Staibano S , Ilardi G , Del Basso De Caro M L , Cavallo L , Cappabianca P , Abbondanza C , Colao A , Bellastella A , Sinisi A A

Pasireotide (SOM230), a somatostatin (SST) analogue targeting multiple SST receptors, is effective in reducing urinary free cortisol in patients with Cushing disease (CD), due to inoperable or recurrent ACTH secreting pituitary adenomas. The efficacy of SOM230 seems to be dependent on the presence of appropriate SSTRs, mainly SSTR2 and 5, on the membrane of tumor cells. Polyclonal antibodies available up to now recognizing cellular intracellular sites of receptors and their re...

0 shares

ea0029p1419 | Pituitary Clinical | ICEECE2012

Immunohistochemical detection of sstr2 and 5 ligand binding domains in 110 pituitary tumors

Rossi V. , Ilardi G. , Massimo M. , Bellastella G. , Visconti D. , Staibano S. , Del Basso De Caro M. , Abbondanza C. , Cavallo L. , De Bellis A. , Cappabianca P. , Colao A. , De Rosa G. , Bellastella A. , Sinisi A.

Classical somatostatin analogues (SST-A), such as octreotide and lanreotide, bind mainly SSTR2 whilst the multiligand pasireotide binds with the highest affinity SSTR5. The selective immunodetection of ligand binding domain (LBD) of SSTR subtypes with specific monoclonal antibodies may be useful to explain the potential efficacy of different SSTA on pituitary tumours growth and/or secretory activity.Patients and Methods: We applied new monoclonal antibod...

0 shares

Endocrine Abstracts

Estradiol Potentiates the Inhibitory Effects of SOM230 on Prostate Cells in vitro Up-regulating Ligand Binding Domain Expression of SSTR2 and 5

ACTH-secreting pituitary adenomas express higher SSTR5 than SSTR2 protein levels by immunohistochenistry using new monoclonal antibodies against SST-binding domains

Immunohistochemical detection of sstr2 and 5 ligand binding domains in 110 pituitary tumors

BiosciAbstracts